Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 40
Filter
1.
Methods Protoc ; 2(4)2019 Nov 15.
Article in English | MEDLINE | ID: mdl-31731599

ABSTRACT

Archived Hematoxylin and Eosin (H&E) stained pathology slides are routinely stored to index formalin-fixed paraffin-embedded (FFPE) sample tissue blocks. FFPE blocks are clinically annotated human tumor specimens that can be valuable in studies decades after the tissue is collected. If stored properly, they have the potential to yield a valuable number of serial sectioned slides for diagnostic or research purposes. However, some retrospective studies are limited in scope because the tissue samples have been depleted or not enough material is available in stored blocks for serial sections. The goal of these studies was to determine if archived H&E-stained slides can be directly reutilized by optimizing methods to de-stain and then re-stain the H&E stained slides to allow the detection of several biomarkers of interest using a conjugated antibody with chromogen multiplex immunohistochemistry procedure. This simple but innovative procedure, combined with image analysis techniques, demonstrates the ability to perform precise detection of relevant markers correlated to disease progression in initially identified tumor regions in tissue. This may add clinical value in retaining H&E slides for further use.

2.
Pathol Oncol Res ; 25(1): 349-359, 2019 Jan.
Article in English | MEDLINE | ID: mdl-29127628

ABSTRACT

The major aim of this study was to evaluate the performance of anti-BRAF V600E (VE1) antibody in colorectal tumors with and without KRAS mutation. KRAS and BRAF are two major oncogenic drivers of colorectal cancer (CRC) that have been frequently described as mutually exclusive, thus the BRAF V600E mutation is not expected to be present in the cases with KRAS mutation. In addition, a review of 25 studies comparing immunohistochemistry (IHC) using the anti-BRAF V600E (VE1) antibody with BRAF V600E molecular testing in 4041 patient samples was included. One-hundred and twenty cases with/without KRAS or BRAF mutations were acquired. The tissue were immunostained with anti-BRAF V600E (VE1) antibody with OptiView DAB IHC detection kit. The KRAS mutated cases with equivocal immunostaining were further evaluated by Sanger sequencing for BRAF V600E mutation. Thirty cases with BRAF V600E mutation showed unequivocal, diffuse, uniform, positive cytoplasmic staining and 30 cases with wild-type KRAS and BRAF showed negative staining with anti-BRAF V600E (VE1) antibody. Out of 60 cases with KRAS mutation, 56 cases (93.3%) were negative for BRAF V600E mutation by IHC. Four cases showed weak, equivocal, heterogeneous, cytoplasmic staining along with nuclear staining in 25-90% of tumor cells. These cases were confirmed to be negative for BRAF V600E mutation by Sanger sequencing. Overall, IHC with anti-BRAF V600E (VE1) antibody using recommended protocol with OptiView detection is optimal for detection of BRAF V600E mutation in CRC. Our data are consistent with previous reports indicating that KRAS and BRAF V600E mutation are mutually exclusive.


Subject(s)
Antibodies, Monoclonal/immunology , Colorectal Neoplasms/diagnosis , Immunohistochemistry/methods , Mutation , Proto-Oncogene Proteins B-raf/genetics , Proto-Oncogene Proteins B-raf/immunology , Animals , Biomarkers, Tumor/genetics , Biomarkers, Tumor/immunology , Biomarkers, Tumor/metabolism , Colorectal Neoplasms/genetics , Colorectal Neoplasms/immunology , Colorectal Neoplasms/metabolism , Humans , Mice , Prognosis , Proto-Oncogene Proteins B-raf/metabolism , Proto-Oncogene Proteins p21(ras)/genetics
3.
Dev Dyn ; 247(3): 542-554, 2018 Mar.
Article in English | MEDLINE | ID: mdl-28631378

ABSTRACT

BACKGROUND: Although normally linked to bone and cartilage development, the Runt-related transcription factor, RUNX2, was reported in the mouse heart during development of the valves. We examined RUNX2 expression and function in the developing avian heart as it related to the epithelial-mesenchymal transition (EMT) in the atrioventricular canal. EMT can be separated into an activation stage involving hypertrophy and cell separation and an invasion stage where cells invade the extracellular matrix. The localization and activity of RUNX2 was explored in relation to these steps in the heart. As RUNX2 was also reported in cancer tissues, we examined its expression in the progression of esophageal cancer in staged tissues. RESULTS: A specific isoform, RUNX2-I, is present and required for EMT by endothelia of the atrioventricular canal. Knockdown of RUNX2-I inhibits the cell-cell separation that is characteristic of initial activation of EMT. Loss of RUNX2-I altered expression of EMT markers to a greater extent during activation than during subsequent cell invasion. Transforming growth factor beta 2 (TGFß2) mediates activation during cardiac endothelial EMT. Consistent with a role in activation, RUNX2-I is regulated by TGFß2 and its activity is independent of similarly expressed Snai2 in regulation of EMT. Examination of RUNX2 expression in esophageal cancer showed its upregulation concomitant with the development of dysplasia and continued expression in adenocarcinoma. CONCLUSIONS: These data introduce the RUNX2-I isoform as a critical early transcription factor mediating EMT in the developing heart after induction by TGFß2. Its expression in tumor tissue suggests a similar role for RUNX2 in the EMT of metastasis. Developmental Dynamics 247:542-554, 2018. © 2017 Wiley Periodicals, Inc.


Subject(s)
Core Binding Factor Alpha 1 Subunit/physiology , Epithelial-Mesenchymal Transition , Animals , Chick Embryo , Chickens , Core Binding Factor Alpha 1 Subunit/genetics , Neoplasms/metabolism , Protein Isoforms , Transcriptional Activation , Transforming Growth Factor beta
4.
Pathology ; 46(6): 509-17, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25014730

ABSTRACT

The most common of all activating BRAF mutations (T1799A) leads to a substitution of valine (V) to glutamic acid (E) at the position 600 of the amino acid sequence. The major goal of this study was to compare detection of the BRAF V600E mutation by DNA sequencing with immunohistochemistry (IHC) using the anti-BRAF V600E (VE1) antibody. Archival formalin fixed, paraffin embedded tissues from 352 patients with colon adenocarcinoma (n = 279) and papillary thyroid carcinoma (n = 73) were evaluated for the BRAF V600E mutation by sequencing and IHC. The discordant cases were re-evaluated by repeat IHC, SNaPshot and next-generation sequencing (NGS). Furthermore, the effect of pre-analytical variables on the utility of this antibody was evaluated in two xenograft mouse models.After resolving 15 initially discordant cases, 212 cases were negative for the BRAF V600E mutation by IHC. Of these, 210 cases (99.1%) were also negative by sequencing and two cases (0.9%) remained discordant. Of the 140 cases that were IHC positive for BRAF V600E, 138 cases were confirmed by sequencing (98.6%) and two cases remained discordant (1.4%). Overall, the negative predictive value was 99.1%, positive predictive value 98.6%, sensitivity 98.6%, specificity 99.1% and overall percentage agreement 98.9% (348/352 cases). Tissue fixation studies indicated that tissues should be fixed for 12-24 h within 2 h of tissue collection with 10% neutral buffered formalin.


Subject(s)
Adenocarcinoma/pathology , Antibodies, Monoclonal/immunology , Biomarkers, Tumor/metabolism , Carcinoma/pathology , Colorectal Neoplasms/pathology , Proto-Oncogene Proteins B-raf/genetics , Thyroid Neoplasms/pathology , Adenocarcinoma/genetics , Adenocarcinoma/metabolism , Animals , Base Sequence , Biomarkers, Tumor/genetics , Carcinoma/genetics , Carcinoma/metabolism , Carcinoma, Papillary , Cell Line, Tumor , Colorectal Neoplasms/genetics , Colorectal Neoplasms/metabolism , Disease Models, Animal , Female , Heterografts , High-Throughput Nucleotide Sequencing , Humans , Immunohistochemistry , Male , Mice , Mutation , Proto-Oncogene Proteins B-raf/immunology , Proto-Oncogene Proteins B-raf/metabolism , Sensitivity and Specificity , Sequence Analysis, DNA , Thyroid Cancer, Papillary , Thyroid Neoplasms/genetics , Thyroid Neoplasms/metabolism
5.
Ann N Y Acad Sci ; 1300: 187-199, 2013 Oct.
Article in English | MEDLINE | ID: mdl-24117642

ABSTRACT

This paper presents commentaries on animal models used for Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) research; acid- and bile-induced chromosomal instability and clonal selection during the progression of BE to EAC; how the components of gastric refluxate, especially acid and bile salts, promote carcinogenesis in metaplastic BE; genome-wide changes in DNA methylation and transcription involved in BE carcinogenesis; the potential role of miRNA in the development of BE and EAC; the effect of inflammatory cytokines linked to obesity on the activation of cell-death pathways and cell survival in BE and esophageal cancer; and the role of autophagy in esophageal cancer development.


Subject(s)
Adenocarcinoma/pathology , Barrett Esophagus/pathology , Cell Transformation, Neoplastic/pathology , Esophageal Neoplasms/pathology , Adenocarcinoma/genetics , Adenocarcinoma/metabolism , Animals , Barrett Esophagus/genetics , Barrett Esophagus/metabolism , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/metabolism , DNA Methylation , Disease Models, Animal , Esophageal Neoplasms/genetics , Esophageal Neoplasms/metabolism , Humans
6.
Ann N Y Acad Sci ; 1300: 296-314, 2013 Oct.
Article in English | MEDLINE | ID: mdl-24117650

ABSTRACT

The following paper on the molecular biology of Barrett's esophagus (BE) includes commentaries on signaling pathways central to the development of BE including Hh, NF-κB, and IL-6/STAT3; surgical approaches for esophagectomy and classification of lesions by appropriate therapy; the debate over the merits of minimally invasive esophagectomy versus open surgery; outcomes for patients with pharyngolaryngoesophagectomy; the applications of neoadjuvant chemotherapy and chemoradiotherapy; animal models examining the surgical models of BE and esophageal adenocarcinoma; the roles of various morphogens and Cdx2 in BE; and the use of in vitro BE models for chemoprevention studies.


Subject(s)
Adenocarcinoma/pathology , Barrett Esophagus/pathology , Cell Transformation, Neoplastic/pathology , Esophageal Neoplasms/pathology , Esophagus/pathology , Adenocarcinoma/genetics , Adenocarcinoma/surgery , Barrett Esophagus/genetics , Barrett Esophagus/surgery , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/metabolism , Esophageal Neoplasms/genetics , Esophageal Neoplasms/surgery , Esophagectomy , Esophagus/metabolism , Esophagus/surgery , Humans , Interleukin-6/genetics , NF-kappa B/genetics
7.
Am J Physiol Gastrointest Liver Physiol ; 305(8): G585-92, 2013 Oct 15.
Article in English | MEDLINE | ID: mdl-23989006

ABSTRACT

Enterohepatic helicobacter species (EHS) infect the intestinal tract and biliary tree, triggering intestinal and hepatic disorders. Helicobacter hepaticus, the prototypic murine EHS, is also associated with inflammation. Necrotizing enterocolitis (NEC) is a devastating disease of premature infants. The cause of NEC is not fully understood, but anomalies of bacterial colonization (dysbiosis) are thought to play an important role in disease onset. To evaluate the effect of H. hepaticus infection on the development of NEC, premature formula-fed rats were kept either in H. hepaticus-free conditions or colonized with H. hepaticus; both groups were exposed to asphyxia and cold stress. The incidence of NEC, expression of Toll-like receptors (TLRs), production of cytokines and mucins, and presence of autophagy regulators were evaluated at the site of injury. H. hepaticus infection increased the incidence of NEC from 39 to 71% and significantly increased levels of TLR4 receptor, expression of proinflammatory cytokines CXCL1, IL-1ß, IL-12, and IL-23, and altered activation of autophagy. H. hepaticus induces inflammation and increases the incidence and severity of experimental NEC; this is consistent with observations in neonates of blooms of proinflammatory microbes just before the onset of NEC. Future studies using rodent NEC models should include testing for H. hepaticus infection. Further studies in neonates of early identification and/or diminution of proinflammatory microbes may be beneficial in decreasing the incidence of NEC.


Subject(s)
Enterocolitis, Necrotizing/microbiology , Helicobacter Infections/microbiology , Helicobacter hepaticus/physiology , Animals , Autophagy , Cytokines/genetics , Cytokines/metabolism , Enterocolitis, Necrotizing/pathology , Female , Gene Expression Regulation/physiology , Helicobacter Infections/pathology , Ileum/metabolism , Ileum/microbiology , Ileum/pathology , Inflammation/metabolism , Inflammation/pathology , Pregnancy , RNA, Bacterial/isolation & purification , Rats , Rats, Sprague-Dawley
8.
World J Gastroenterol ; 19(15): 2307-12, 2013 Apr 21.
Article in English | MEDLINE | ID: mdl-23613623

ABSTRACT

Barrett's esophagus (BE) is a metaplastic lesion of the distal esophagus arising as a consequence of chronic gastroesophageal reflux disease. Multiple studies show that BE is associated with increased risk of esophageal adenocarcinoma (EAC). Epidemiological studies and animal models demonstrate that chronic inflammation triggered by repeated exposure to refluxate predisposes to the development of BE and EAC. The chronic inflammation is associated with cytokine alterations. Interleukin 6 (IL-6) is a cytokine that stimulates cell proliferation and apoptosis resistance is frequently increased in different cancers. Importantly, IL-6 and transcriptional factor signal transducer and activator of transcription 3 (STAT3) that is activated by IL-6 are also increased in BE and EAC. This review critically appraises the role of IL-6/STAT3 pathway in progression of BE to EAC from the published evidence currently available.


Subject(s)
Barrett Esophagus/metabolism , Gene Expression Regulation , Interleukin-6/physiology , Animals , Apoptosis , Bile Acids and Salts/metabolism , Colonic Neoplasms/metabolism , Esophageal Neoplasms/metabolism , Female , Gene Expression Regulation, Neoplastic , Humans , Inflammation , Male , Mice , STAT3 Transcription Factor/metabolism , Sex Factors
9.
Exp Ther Med ; 3(5): 845-852, 2012 May.
Article in English | MEDLINE | ID: mdl-22529877

ABSTRACT

Chronic inflammation increases lymphoma risk. Chronic inflammation exposes cells to increased reactive oxygen species (ROS). Constant exposure to ROS selects for oxidative stress-resistant cells with upregulated anti-oxidant defense enzymes. The impact of oxidative stress resistance on the redox biology and chemotherapy response in lymphoma has not been rigorously tested. To measure the effect of antioxidant defense enzyme upregulation in lymphoid cells, we created oxidative stress-resistant WEHI7.2 thymic lymphoma cell variants. We selected a population of WEHI7.2 cells for resistance to hydrogen peroxide and constructed catalase-overexpressing WEHI7.2 transfectants. The WEHI7.2 variants had: i) increased catalase and total superoxide dismutase activities; ii) an altered GSSG/2GSH redox potential; iii) a more oxidized NADP(+)/NADPH pool; and iv) increased phase 2 enzymes, NAD(P)H:quinone oxidoreductase and glutathione S-transferases µ and π. Regression analysis showed a correlation between the GSSG/2GSH redox potential and the increased phase 2 enzyme activities. As predicted from the anti-oxidant defense enzyme profile, the variants were more resistant to the oxidants hydrogen peroxide and paraquat. The variants exhibited resistance to the common lymphoma chemotherapeutics, cyclophosphamide, doxorubicin, vincristine and glucocorticoids. These data indicate that chronic ROS exposure results in lymphoid cells with multiple changes in their redox biology and a chemoresistance phenotype. These data further suggest that lymphomas that arise at the site of chronic inflammation develop chemoresistance due to a combination of drug detoxification and removal of ROS.

10.
Am J Physiol Gastrointest Liver Physiol ; 302(8): G864-72, 2012 Apr 15.
Article in English | MEDLINE | ID: mdl-22301112

ABSTRACT

Beclin-1 has a central role in the regulation of autophagy. Barrett's esophagus (BE) is associated with a significantly increased risk for the development of esophageal adenocarcinoma (EAC). In the current study, we evaluated the role of Beclin-1 and autophagy in the EAC. Biopsies obtained from patients with BE and EAC, tissues from a rat model of BE and EAC, and esophageal cell lines were evaluated for the expression of Beclin-1 by immunohistochemistry, immunoblotting, or RT-PCR. Since reflux of bile acids is important in EAC, we also evaluated the effect of exposure to deoxycholic acid (DCA) on autophagy and Beclin-1 expression. Beclin-1 expression was high in squamous epithelium and nondysplastic BE, whereas its expression was low in dysplastic BE and EAC. The same pattern of expression was observed in rat tissues and in esophageal cell lines. Normal esophageal epithelium and HET-1A cells (derived from normal squamous epithelium) show high levels of Beclin-1, but lower levels of Beclin-1 were found in BE and EAC cell lines (CP-A, CP-C, and OE33). Acute exposure to DCA led to increased Beclin-1 expression and increased autophagy as evaluated by electron microscopy and counting percentage of GFP-LC3-positive BE cells with punctate pattern. In contrast, chronic exposure to DCA did not result in the alteration of Beclin-1 levels or autophagy. In summary, these data suggest that autophagy is initially activated in response to bile acids, but chronic exposure to bile acids leads to decreased Beclin-1 expression and autophagy resistance.


Subject(s)
Adenocarcinoma/pathology , Apoptosis Regulatory Proteins/biosynthesis , Apoptosis Regulatory Proteins/physiology , Deoxycholic Acid/physiology , Esophageal Neoplasms/pathology , Membrane Proteins/biosynthesis , Membrane Proteins/physiology , Amino Acids/deficiency , Animals , Autophagy , Barrett Esophagus/pathology , Beclin-1 , Bile Acids and Salts/metabolism , Blotting, Western , Cell Line, Tumor , Cell Proliferation , Deoxycholic Acid/pharmacology , Disease Progression , Humans , Immunohistochemistry , Microarray Analysis , Microscopy, Confocal , Microscopy, Electron, Transmission , RNA/biosynthesis , RNA/genetics , RNA, Small Interfering/pharmacology , Rats , Real-Time Polymerase Chain Reaction
11.
PLoS One ; 6(8): e23835, 2011.
Article in English | MEDLINE | ID: mdl-21887327

ABSTRACT

Apoptosis resistance is a hallmark of cancer cells. Typically, bile acids induce apoptosis. However during gastrointestinal (GI) tumorigenesis the cancer cells develop resistance to bile acid-induced cell death. To understand how bile acids induce apoptosis resistance we first need to identify the molecular pathways that initiate apoptosis in response to bile acid exposure. In this study we examined the mechanism of deoxycholic acid (DCA)-induced apoptosis, specifically the role of Na(+)/H(+) exchanger (NHE) and Na(+) influx in esophageal cells. In vitro studies revealed that the exposure of esophageal cells (JH-EsoAd1, CP-A) to DCA (0.2 mM-0.5 mM) caused lysosomal membrane perturbation and transient cytoplasmic acidification. Fluorescence microscopy in conjunction with atomic absorption spectrophotometry demonstrated that this effect on lysosomes correlated with influx of Na(+), subsequent loss of intracellular K(+), an increase of Ca(2+) and apoptosis. However, ethylisopropyl-amiloride (EIPA), a selective inhibitor of NHE, prevented Na(+), K(+) and Ca(2+) changes and caspase 3/7 activation induced by DCA. Ouabain and amphotericin B, two drugs that increase intracellular Na(+) levels, induced similar changes as DCA (ion imbalance, caspase3/7 activation). On the contrary, DCA-induced cell death was inhibited by medium with low a Na(+) concentrations. In the same experiments, we exposed rat ileum ex-vivo to DCA with or without EIPA. Severe tissue damage and caspase-3 activation was observed after DCA treatment, but EIPA almost fully prevented this response. In summary, NHE-mediated Na(+) influx is a critical step leading to DCA-induced apoptosis. Cells tolerate acidification but evade DCA-induced apoptosis if NHE is inhibited. Our data suggests that suppression of NHE by endogenous or exogenous inhibitors may lead to apoptosis resistance during GI tumorigenesis.


Subject(s)
Apoptosis/drug effects , Cations/metabolism , Deoxycholic Acid/pharmacology , Esophagus/pathology , Gastrointestinal Neoplasms/pathology , Sodium-Hydrogen Exchangers/physiology , Bile Acids and Salts/pharmacology , Cells, Cultured , Gastrointestinal Neoplasms/etiology , Humans , Hydrogen/metabolism , Hydrogen-Ion Concentration , Lysosomes , Sodium/metabolism , Sodium-Hydrogen Exchangers/antagonists & inhibitors
12.
Ann N Y Acad Sci ; 1232: 1-17, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21950804

ABSTRACT

Although the prevalence of Barrett's esophagus (BE) is rising no data exist for racial minorities on prevalence in the general population. Minorities have a lower prevalence than Caucasians, and yet age, smoking, abdominal obesity, and Helicobacter pylori are all risk factors. Metabolic changes induced by adipocytokines and the apparently strong association between obesity, central adiposity, and BE may lead to reconsideration of some aspects of the natural history of BE. There is lack of experimental evidence on acid sensitivity and BE, which is hyposensitive compared to esophageal reflux disease. Reactive nitrogen and oxygen species lead to impaired expression of tumor suppressor genes, which can lead to cancer development; thus, antioxidants may be protective. Gastroesophageal reflux disease may be considered an immune-mediated disease starting at the submucosal layer; the cytokine profile of the mucosal immune response may explain the different outcome of gastroesophageal reflux.


Subject(s)
Barrett Esophagus/epidemiology , Barrett Esophagus/etiology , Humans , Incidence , Prevalence
13.
Ann N Y Acad Sci ; 1232: 93-113, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21950809

ABSTRACT

The following on proton pump inhibitors and chemoprevention in Barrett's esophagus includes commentaries on normalization of esophageal refluxate; the effects of 5-HT(4) agonists on EGF secretion and of lubripristone on chloride channels agents; the role of Campylobacter toxin production; the deleterious effects of unconjugated bile acids; the role of baclofen in nonacid reflux; the threshold for adequate esophageal acid exposure; the effects of proton pump inhibitor (PPI) therapy on normalization of esophageal pH and on cell proliferation; the role of the phenotype of cellular proliferation on the effects of PPI therapy; and the value of Symptom Index and Symptom Association Probability in the evaluation of potential response to treatment.


Subject(s)
Barrett Esophagus/drug therapy , Proton Pump Inhibitors/therapeutic use , Barrett Esophagus/pathology , Barrett Esophagus/prevention & control , Chemoprevention , Humans
14.
Ann N Y Acad Sci ; 1232: 114-39, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21950810

ABSTRACT

The following on proton pump inhibitors (PPIs) and chemoprevention in relation to Barrett's esophagus includes commentaries on 48-h pH monitoring, pH-impedence, bile acid testing, dyspepsia, long/short segment Barrett's esophagus, nonerosive reflux disease (NERD), functional heartburn, dual-release delivery PPIs, immediate-release PPIs, long-term PPI use, prokinetic agents, obesity, baclofen, nocturnal acid breakthrough, nonsteroidal anti-inflammatory drugs (NSAIDs), and new PPIs.


Subject(s)
Barrett Esophagus/drug therapy , Chemoprevention , Proton Pump Inhibitors/therapeutic use , Humans , Monitoring, Physiologic , Treatment Outcome
15.
Ann N Y Acad Sci ; 1232: 140-55, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21950811

ABSTRACT

The following on endoscopic treatments of Barrett's esophagus includes commentaries on indications for endoscopic treatments; endo-luminal plication procedures; the cellular modifications induced by the endoscopic ablation therapies; eradication by banding without resection; the evaluation of complete ablation; recurrence after ablation; association of antireflux surgery; radiofrequency ablation; and nondysplastic Barrett's esophagus.


Subject(s)
Barrett Esophagus/therapy , Endoscopy/methods , Humans
16.
Ann N Y Acad Sci ; 1232: 196-209, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21950814

ABSTRACT

The following on surveillance and reversal of Barrett's esophagus (BE) includes commentaries on criteria for surveillance even when squamous epithelium stains normally with a variety of biomarkers; the long-term follow-up of surgery versus endoscopic ablation of BE; the recommended surveillance intervals in patients without dysplasia; the sampling problems related to anatomic changes following fundoplication; the value of tissue spectroscopy and optical coherence tomography; the cost-effectiveness of biopsy protocols for surveillance; the quality of life of Barrett's patients; and risk stratification and surveillance strategies.


Subject(s)
Barrett Esophagus/epidemiology , Population Surveillance , Barrett Esophagus/therapy , Humans , Tomography, Optical Coherence
17.
Ann N Y Acad Sci ; 1232: 230-47, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21950816

ABSTRACT

The following on prevalence and incidence of adenocarcinomas in Barrett's esphophagus (BE) includes commentaries on the mechanisms of a potential protective effect of proton pump inhibitors (PPIs) on progression of BE to high-grade dysplasia; evaluation of the role of PPIs in decreasing the risk of degeneration; the geographical variations of incidence of BE; the role of the nonmorphologic biomarkers; the relationship between length of BE and development of cancer; the confounding factors in incidence rates of BE; the role of the increase of cell differentiation and apoptosis induced by PPIs in the diminution of cancer risk; the frequency of occult neoplastic foci and unsuspected invasive cancer in surgical specimens; the influence on the indications of endoscopic therapy; the overestimation of regression in surgical series; attempts to evaluate the reasons for variations of cancer incidence in the literature; and progress in screening and surveillance for BE.


Subject(s)
Adenocarcinoma/epidemiology , Barrett Esophagus/epidemiology , Esophageal Neoplasms/epidemiology , Disease Progression , Humans , Incidence , Prevalence , Proton Pump Inhibitors/therapeutic use
18.
Ann N Y Acad Sci ; 1232: 381-91, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21950830

ABSTRACT

The following on molecular mechanisms of Barrett's esophagus and adenocarcinoma contains commentaries on the mechanism of bile and gastric acid induced damage; the roles of BMP-4 and CDX-2 in the development of intestinal metaplasia; the transcription factors driving intestinalization in Barrett's esophagus; the contribution of bone marrow to metaplasia and adenocarcinoma; activation and inactivation of transcription factors; and a novel study design targeting molecular pathways in Barrett's esophagus.


Subject(s)
Adenocarcinoma/genetics , Barrett Esophagus/genetics , Esophageal Neoplasms/genetics , Adenocarcinoma/physiopathology , Barrett Esophagus/physiopathology , Bile Acids and Salts/physiology , Bone Morphogenetic Protein 4/physiology , CDX2 Transcription Factor , DNA Damage , Esophageal Neoplasms/physiopathology , Homeodomain Proteins/physiology , Humans , Trans-Activators/physiology
19.
Am J Physiol Gastrointest Liver Physiol ; 300(2): G292-302, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21127259

ABSTRACT

Barrett's esophagus (BE) is a premalignant condition, where normal squamous epithelium is replaced by intestinal epithelium. BE is associated with an increased risk of developing esophageal adenocarcinoma (EAC). However, the BE cell of origin is not clear. We hypothesize that BE tissue originates from esophageal squamous cells, which can differentiate to columnar cells as a result of repeated exposure to gastric acid and bile acids, two components of refluxate implicated in BE pathology. To test this hypothesis, we repeatedly exposed squamous esophageal HET1A cells to 0.2 mM bile acid (BA) cocktail at pH 5.5 and developed an HET1AR-resistant cell line. These cells are able to survive and proliferate after repeated 2-h treatments with BA at pH 5.5. HET1AR cells are resistant to acidification and express markers of columnar differentiation, villin, CDX2, and cytokeratin 8/18. HET1AR cells have increased amounts of reactive oxygen species, concomitant with a decreased level and activity of manganese superoxide dismutase compared with parental cells. Furthermore, HET1AR cells express proteins and activate signaling pathways associated with inflammation, cell survival, and tumorigenesis that are thought to contribute to BE and EAC development. These include STAT3, NF-κB, epidermal growth factor receptor (EGFR), cyclooxygenase-2, interleukin-6, phosphorylated mammalian target of rapamycin (p-mTOR), and Mcl-1. The expression of prosurvival and inflammatory proteins and resistance to cell death could be partially modified by inhibition of STAT3 signaling. In summary, our study shows that long-term exposure of squamous cells to BA at acidic pH causes the cells to display the same characteristics and markers as BE.


Subject(s)
Barrett Esophagus/etiology , Bile Acids and Salts/pharmacology , Esophagus/drug effects , Acids/pharmacology , Adenocarcinoma/metabolism , Biomarkers/metabolism , Cell Line, Transformed , Down-Regulation , Drug Resistance , Epithelium/metabolism , Esophageal Neoplasms/metabolism , Esophagus/cytology , Esophagus/metabolism , Humans , Hydrogen-Ion Concentration , Interleukin-6/metabolism , Metaplasia/metabolism , NF-kappa B/metabolism , Reactive Oxygen Species/metabolism , STAT3 Transcription Factor/antagonists & inhibitors , STAT3 Transcription Factor/metabolism , Signal Transduction , Superoxide Dismutase/metabolism , Up-Regulation
20.
Gut ; 59(12): 1606-16, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20876775

ABSTRACT

OBJECTIVE: Barrett's oesophagus is a premalignant disease associated with oesophageal adenocarcinoma. The major goal of this study was to determine the mechanism responsible for bile acid-induced alteration in intracellular pH (pH(i)) and its effect on DNA damage in cells derived from normal oesophagus (HET1A) or Barrett's oesophagus (CP-A). DESIGN: Cells were exposed to bile acid cocktail (BA) and/or acid in the presence/absence of inhibitors of nitric oxide synthase (NOS) or sodium-hydrogen exchanger (NHE). Nitric oxide (NO), pH(i) and DNA damage were measured by fluorescent imaging and comet assay. Expression of NHE1 and NOS in cultured cells and biopsies from Barrett's oesophagus or normal squamous epithelium was determined by RT-PCR, immunoblotting or immunohistochemistry. RESULTS: A dose dependent decrease in pH(i) was observed in CP-A cells exposed to BA. This effect of BA is the consequence of NOS activation and increased NO production, which leads to NHE inhibition. Exposure of oesophageal cells to acid in combination with BA synergistically decreased pH(i). The decrease was more pronounced in CP-A cells and resulted in >2-fold increase in DNA damage compared to acid treatment alone. Examination of biopsies and cell lines revealed robust expression of NHE1 in Barrett's oesophagus but an absence of NHE1 in normal epithelium. CONCLUSIONS: The results of this study identify a new mechanism of bile acid-induced DNA damage. We found that bile acids present in the refluxate activate immediately all three isoforms of NOS, which leads to an increased NO production and NHE inhibition. This consequently results in increased intracellular acidification and DNA damage, which may lead to mutations and cancer progression. Therefore, we propose that in addition to gastric reflux, bile reflux should be controlled in patients with Barrett's oesophagus.


Subject(s)
Barrett Esophagus/genetics , Bile Acids and Salts/pharmacology , DNA Damage , Esophagus/drug effects , Sodium-Hydrogen Exchangers/genetics , Barrett Esophagus/metabolism , Barrett Esophagus/pathology , Cation Transport Proteins/biosynthesis , Cation Transport Proteins/genetics , Cell Line , Dose-Response Relationship, Drug , Drug Synergism , Enzyme Activation/drug effects , Esophagus/metabolism , Humans , Hydrochloric Acid/pharmacology , Hydrogen-Ion Concentration/drug effects , Nitric Oxide/physiology , Nitric Oxide Synthase/metabolism , RNA, Messenger/genetics , Reverse Transcriptase Polymerase Chain Reaction/methods , Sodium-Hydrogen Exchanger 1 , Sodium-Hydrogen Exchangers/biosynthesis , Sodium-Hydrogen Exchangers/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...